GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 May 24

PMID 38789846

Authors

Yadong Wang

Xiaosan Fang

Hao Xie

Xiaoming Wang

Affiliations

Soon will be listed here.

Abstract

Primary liver cancer, specifically hepatocellular carcinoma (HCC), is a major global health concern. GCNT3 has been identified as an oncogene in various human malignancies. This investigation aimed to discover the GCNT3 function in HCC. The present study employed integrated bioinformatics analyses to assess the expression pattern, prognostic implications, and putative function of GCNT3 in HCC. Transwell flow cytometry, CCK-8, and wound healing assays were performed to examine HCC cell growth, cell cycle, apoptosis, invasion, and migration. In addition, the epithelial-mesenchymal transition (EMT) markers and PI3K/AKT mechanism markers were examined via western blot analysis to elucidate the underlying mechanisms. In HCC, GCNT3 was significantly overexpressed, which was connected with enhanced tumor aggressiveness and an unfavorable prognosis of individuals. In vitro experiments demonstrated that elevated levels of GCNT3 promoted cell growth, migration, cell cycle development, and invasion, in addition to EMT, while suppressing apoptosis. Conversely, knockdown of GCNT3 exerted the opposite effects. GCNT3 overexpression increased PI3K/AKT phosphorylation in HCC cells, and LY294002 counteracted the impacts of upregulated GCNT3 on cell cycle, migration, invasion, proliferation, and EMT in HCC. The investigation showed that GCNT3 may enhance HCC progression and EMT by stimulating PI3K/AKT mechanism.

Citing Articles

GCNT3 promotes the proliferation, apoptosis, invasion, and migration of breast cancer through the PI3K/AKT pathway.

Li Y, Ren Z, Wu T, Zhang N, He Z Transl Cancer Res. 2024; 13(11):6381-6393.

PMID: 39697709 PMC: 11651748. DOI: 10.21037/tcr-2024-2248.

References

Bagdonaite I, Pallesen E, Ye Z, Vakhrushev S, Marinova I, Nielsen M . O-glycan initiation directs distinct biological pathways and controls epithelial differentiation. EMBO Rep. 2020; 21(6):e48885. PMC: 7271655. DOI: 10.15252/embr.201948885. View

Bai C, Chen D . NRCAM acts as a prognostic biomarker and promotes the tumor progression in gastric cancer via EMT pathway. Tissue Cell. 2022; 77:101859. DOI: 10.1016/j.tice.2022.101859. View

Bugide S, Gonugunta V, Penugurti V, Malisetty V, Vadlamudi R, Manavathi B . HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell Oncol (Dordr). 2017; 40(2):133-144. DOI: 10.1007/s13402-016-0308-2. View

Fernandez L, Sanchez-Martinez R, Vargas T, Herranz J, Martin-Hernandez R, Mendiola M . The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance. Sci Rep. 2018; 8(1):8485. PMC: 5981315. DOI: 10.1038/s41598-018-26468-4. View

Fresno Vara J, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M . PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30(2):193-204. DOI: 10.1016/j.ctrv.2003.07.007. View

Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K, Hayashi S . Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020; 53:102659. PMC: 7048625. DOI: 10.1016/j.ebiom.2020.102659. View

Han H, Qiu Y, Shi Y, Wen W, He X, Dong L . Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe. Theranostics. 2018; 8(12):3268-3274. PMC: 6010994. DOI: 10.7150/thno.24711. View

Han S, Kwon S, Kim K . Contribution of mechanical homeostasis to epithelial-mesenchymal transition. Cell Oncol (Dordr). 2022; 45(6):1119-1136. DOI: 10.1007/s13402-022-00720-6. View

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

10.

Jiang P, Xu L, Ning J, Cheng F . GREM1 is a potential biomarker for the progression and prognosis of bladder cancer. World J Surg Oncol. 2023; 21(1):255. PMC: 10463405. DOI: 10.1186/s12957-023-03128-0. View

11.

Li Q, Ran P, Zhang X, Guo X, Yuan Y, Dong T . Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion. Cell Physiol Biochem. 2018; 50(3):987-1004. DOI: 10.1159/000494482. View

12.

Liu J, Zhang Y, Liu W, Zhang Q, Xiao H, Song H . MiR-BART1-5p targets core 2β-1,6-acetylglucosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer. Virology. 2020; 541:63-74. DOI: 10.1016/j.virol.2019.12.004. View

13.

Madunic K, Zhang T, Mayboroda O, Holst S, Stavenhagen K, Jin C . Colorectal cancer cell lines show striking diversity of their O-glycome reflecting the cellular differentiation phenotype. Cell Mol Life Sci. 2020; 78(1):337-350. PMC: 7867528. DOI: 10.1007/s00018-020-03504-z. View

14.

Mikhail S, Cosgrove D, Zeidan A . Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014; 14(10):1205-18. DOI: 10.1586/14737140.2014.949246. View

15.

Njei B, Rotman Y, Ditah I, Lim J . Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2014; 61(1):191-9. PMC: 4823645. DOI: 10.1002/hep.27388. View

16.

Nouri-Vaskeh M, Alizadeh L, Hajiasgharzadeh K, Mokhtarzadeh A, Halimi M, Baradaran B . The role of HSP90 molecular chaperones in hepatocellular carcinoma. J Cell Physiol. 2020; 235(12):9110-9120. DOI: 10.1002/jcp.29776. View

17.

Rao C, Janakiram N, Madka V, Kumar G, Scott E, Pathuri G . Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Cancer Res. 2016; 76(7):1965-74. DOI: 10.1158/0008-5472.CAN-15-2820. View

18.

Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K . Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Sci. 2017; 108(10):1996-2003. PMC: 5623735. DOI: 10.1111/cas.13341. View

19.

Sumardika I, Youyi C, Kondo E, Inoue Y, Ruma I, Murata H . β-1,3-Galactosyl--Glycosyl-Glycoprotein β-1,6--Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility. Oncol Res. 2017; 26(3):431-444. PMC: 7844831. DOI: 10.3727/096504017X15031557924123. View

20.

Sun J, Dong Z, Chang Z, Liu H, Jiang Q, Zhang D . MARCH6 promotes hepatocellular carcinoma development through up-regulation of ATF2. BMC Cancer. 2021; 21(1):827. PMC: 8285810. DOI: 10.1186/s12885-021-08540-x. View